Cell therapy for the treatment of coronary heart disease: A critical appraisal

Nature Reviews Cardiology

Volumn 7, Issue 4, 2010, Pages 204-215

  Wollert, Kal C ^a   Drexler, Helmut ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VASCULOTROPIN;

ACUTE HEART INFARCTION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CLOT LYSIS; BONE MARROW CELL; CD34 SELECTION; CELL FUNCTION; CELL ISOLATION; CELL RETENTION; CELL SURVIVAL; CELL THERAPY; CELL TRANSFER; CELL TYPE; CHRONIC MYOCARDIAL ISCHEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENGRAFTMENT; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARACRINE SIGNALING; PATIENT SAFETY; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STRATEGIC PLANNING; TREATMENT INDICATION;

CORONARY ARTERY DISEASE; HUMANS; MULTIPOTENT STEM CELLS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PARACRINE COMMUNICATION; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 77950300420     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.1     Document Type: Review

References (141)

1. velagaleti, R. S. et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 118, 2057-2062 (2008).
2. McMurray, J. J. &Pfeffer, M. A. Heart failure. Lancet 365, 1877-1889 (2005).
3. Soonpaa, M. H., Koh, G. Y., Klug, M. G. &Field, L. J. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science 264, 98-101 (1994).
4. Taylor, D. A. et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat. Med. 4, 929-933 (1998).
5. Robey, T. e., Saiget, M. K., Reinecke, H. &Murry, C. e. Systems approaches to preventing transplanted cell death in cardiac repair. J. Mol. Cell. Cardiol. 45, 567-581 (2008).
6. Chien, K. R., Domian, I. J. &Parker, K. K. Cardiogenesis and the complex biology of regenerative cardiovascular medicine. Science 322, 1494-1497 (2008).
7. Dowell, J. D., Rubart, M., Pasumarthi, K. B., Soonpaa, M. H. &Field, L. J. Myocyte and myogenic stem cell transplantation in the heart. Cardiovasc. Res. 58, 336-350 (2003).
8. Blau, H. M., Brazelton, T. R. &Weimann, J. M. The evolving concept of a stem cell: entity or function? Cell 105, 829-841 (2001).
9. Wagers, A. J. &Weissman, I. L. Plasticity of adult stem cells. Cell 116, 639-648 (2004).
10. Wollert, K. C. &Drexler, H. Clinical applications of stem cells for the heart. Circ. Res. 96, 151-163 (2005).
11. Wollert, K. C. et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364, 141-148 (2004).
12. Meyer, G. P. et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113, 1287-1294 (2006).
13. Meyer, G. P. et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur. Heart J. 30, 2978-2984 (2009).
14. Schaefer, A. et al. Impact of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: results from the BOOST trial. Eur. Heart J. 27, 929-935 (2006).
15. Janssens, S. et al. Autologous bone marrowderived stem-cell transfer in patients with STsegment elevation myocardial infarction: doubleblind, randomised controlled trial. Lancet 367, 113-121 (2006).
16. Herbots, L. et al. Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study. Eur. Heart J. 30, 662-670 (2009).
17. Schächinger, v. et al. Intracoronary bone marrowderived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355, 1210-1221 (2006).
18. Dill, T. et al. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (RePAIR-AMI) cardiac magnetic resonance imaging substudy. Am. Heart J. 157, 541-547 (2009).
19. Lunde, K. et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 355, 1199-1209 (2006).
20. Lunde, K. et al. Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months' follow-up. J. Am. Coll. Cardiol. 51, 674-676 (2008).
21. Seeger, F. H., Tonn, T., Krzossok, N., Zeiher, A. M. &Dimmeler, S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur. Heart J. 28, 766-772 (2007).
22. Huikuri, H. v. et al. effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur. Heart J. 29, 2723-2732 (2008).
23. Tendera, M. et al. Intracoronary infusion of bone marrow-derived selected CD34+ CXCR4+ cells and non-selected mononuclear cells in patients with acute STeMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (ReGeNT) Trial. Eur. Heart J. 30, 1313-1321 (2009).
24. van der Laan, A. et al. Bone marrow cell therapy after acute myocardial infarction: the HeBe trial in perspective, first results. Neth. Heart J. 16, 436-439 (2008).
25. Piek, J. J. Intracoronary infusion of mononuclear cells after primary percutaneous coronary intervention: The HeBe trial. Presented at the AHA 2008 Scientific Sessions.
26. Mansour, S. et al. Intracoronary delivery of hematopoietic bone marrow stem cells and luminal loss of the infarct-related artery in patients with recent myocardial infarction. J. Am. Coll. Cardiol. 47, 1727-1730 (2006).
27. Lipinski, M. J. et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J. Am. Coll. Cardiol. 50, 1761-1767 (2007).
28. Martin-Rendon, e. et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur. Heart J. 29, 1807-1818 (2008).
29. Menasché, P. et al. Myoblast transplantation for heart failure. Lancet 357, 279-280 (2001).
30. Menasché, P. Skeletal myoblasts as a therapeutic agent. Prog. Cardiovasc. Dis. 50, 7-17 (2007).
31. Menasché, P. et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117, 1189-1200 (2008).
32. Menasché, P. Stem cell therapy for heart failure: are arrhythmias a real safety concern? Circulation 119, 2735-2740 (2009).
33. Assmus, B. et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 355, 1222-1232 (2006).
34. Losordo, D. W. et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 115, 3165-3172 (2007).
35. Tse, H. F. et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTeCT-CAD trial). Eur. Heart J. 28, 2998-3005 (2007).
36. van Ramshorst, J. et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 301, 1997-2004 (2009).
37. Arora, R. R. et al. The multicenter study of enhanced external counterpulsation (MUSTeeCP): effect of eeCP on exercise-induced myocardial ischemia and anginal episodes. J. Am. Coll. Cardiol. 33, 1833-1840 (1999).
38. Leon, M. B. et al. A blinded, randomized, placebocontrolled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J. Am. Coll. Cardiol. 46, 1812-1819 (2005).
39. Reffelmann, T., Könemann, S. &Kloner, R. A. Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. J. Am. Coll. Cardiol. 53, 305-308 (2009).
40. Møller, J. e. et al. Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction. Am. Heart J. 151, 419-425 (2006).
41. Yokoyama, S. et al. A strategy of retrograde injection of bone marrow mononuclear cells into the myocardium for the treatment of ischemic heart disease. J. Mol. Cell. Cardiol. 40, 24-34 (2006).
42. Silva, S. A. et al. Autologous bone-marrow mononuclear cell transplantation after acute myocardial infarction: comparison of two delivery techniques. Cell Transplant. 18, 343-352 (2009).
43. Perin, e. C. &López, J. Methods of stem cell delivery in cardiac diseases. Nat. Clin. Pract. Cardiovasc. Med. 3 (Suppl. 1), 110-113 (2006).
44. Bartunek, J. et al. Delivery of biologics in cardiovascular regenerative medicine. Clin. Pharmacol. Ther. 85, 548-552 (2009).
45. de Silva, R. et al. X-ray fused with magnetic resonance imaging (XFM) to target endomyocardial injections: validation in a swine model of myocardial infarction. Circulation 114, 2342-2350 (2006).
46. Schächinger, v. et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the RePAIR-AMI trial. Eur. Heart J. 27, 2775-2783 (2006).
47. Yousef, M. et al. The BALANCe Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 53, 2262-2269 (2009).
48. Hofmann, M. et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111, 2198-2202 (2005).
49. Schächinger, v. et al. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation 118, 1425-1432 (2008).
50. Haider, H. K. &Ashraf, M. Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J. Mol. Cell. Cardiol. 45, 554-566 (2008).
51. Menasché, P. Skeletal myoblasts and cardiac repair. J. Mol. Cell. Cardiol. 45, 545-553 (2008).
52. Kissel, C. K. et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J. Am. Coll. Cardiol. 49, 2341-2349 (2007).
53. Spyridopoulos, I. et al. Telomere gap between granulocytes and lymphocytes is a determinant for hematopoetic progenitor cell impairment in patients with previous myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 28, 968-974 (2008).
54. Werner, N. et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353, 999-1007 (2005).
55. Dimmeler, S. &Leri, A. Aging and disease as modifiers of efficacy of cell therapy. Circ. Res. 102, 1319-1330 (2008).
56. Aicher, A. et al. essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9, 1370-1376 (2003).
57. Landmesser, U. et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110, 1933-1939 (2004).
58. Sasaki, K. et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer Ave9488 enhances their functional activity for cell therapy. Proc. Natl Acad. Sci. USA 103, 14537-14541 (2006).
59. Sorrentino, S. A. et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptorgamma agonist rosiglitazone. Circulation 116, 163-173 (2007).
60. Britten, M. B. et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARe-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 108, 2212-2218 (2003).
61. Assmus, B. et al. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARe-CHD Registry. Circ. Res. 100, 1234-1241 (2007).
62. Aicher, A. et al. Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circulation 114, 2823-2830 (2006).
63. Zen, K. et al. Myocardium-targeted delivery of endothelial progenitor cells by ultrasoundmediated microbubble destruction improves cardiac function via an angiogenic response. J. Mol. Cell. Cardiol. 40, 799-809 (2006).
64. Ghanem, A. et al. Focused ultrasound-induced stimulation of microbubbles augments sitetargeted engraftment of mesenchymal stem cells after acute myocardial infarction. J. Mol. Cell. Cardiol. 47, 411-418 (2009).
65. Chavakis, e., Urbich, C. &Dimmeler, S. Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J. Mol. Cell. Cardiol. 45, 514-522 (2008).
66. Kohno, T. et al. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc. Res. 81, 565-573 (2009).
67. Askari, A. T. et al. effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362, 697-703 (2003).
68. Yamaguchi, J. et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 107, 1322-1328 (2003).
69. Penn, M. S. Importance of the SDF-1:CXCR4 axis in myocardial repair. Circ. Res. 104, 1133-1135 (2009).
70. Tang, Y. L. et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ. Res. 104, 1209-1216 (2009).
71. Chavakis, e. et al. Role of beta2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J. Exp. Med. 201, 63-72 (2005).
72. Wu, Y. et al. essential role of ICAM-1/CD18 in mediating ePC recruitment, angiogenesis, and repair to the infarcted myocardium. Circ. Res. 99, 315-322 (2006).
73. Chavakis, e. et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ. Res. 100, 204-212 (2007).
74. Carmona, G., Chavakis, e., Koehl, U., Zeiher, A. M. &Dimmeler, S. Activation of epac stimulates integrin-dependent homing of progenitor cells. Blood 111, 2640-2646 (2008).
75. Spyridopoulos, I. et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 110, 3136-3142 (2004).
76. Li, X. et al. AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 28, 1789-1795 (2008).
77. Shao, H. et al. Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells 26, 1376-1384 (2008).
78. Niagara, M. I., Haider, H. K., Jiang, S. &Ashraf, M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ. Res. 100, 545-555 (2007).
79. Pasha, Z. et al. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc. Res. 77, 134-142 (2008).
80. Bartunek, J. et al. Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium. Am. J. Physiol. Heart Circ. Physiol. 292, H1095-H1104 (2007).
81. Hahn, J. Y. et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J. Am. Coll. Cardiol. 51, 933-943 (2008).
82. Nadeau, S. I. &Landry, J. Mechanisms of activation and regulation of the heat shocksensitive signaling pathways. Adv. Exp. Med. Biol. 594, 100-113 (2007).
83. Laflamme, M. A. et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25, 1015-1024 (2007).
84. Maurel, A. et al. Can cold or heat shock improve skeletal myoblast engraftment in infarcted myocardium? Transplantation 80, 660-665 (2005).
85. Suzuki, K. et al. Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation 102 (Suppl. 3), 216-221 (2000).
86. Penn, M. S. &Mangi, A. A. Genetic enhancement of stem cell engraftment, survival, and efficacy. Circ. Res. 102, 1471-1482 (2008).
87. Tang, Y. L. et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J. Am. Coll. Cardiol. 46, 1339-1350 (2005).
88. Li, W. et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 25, 2118-2127 (2007).
89. Shujia, J., Haider, H. K., Idris, N. M., Lu, G. &Ashraf, M. Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc. Res. 77, 525-533 (2008).
90. Gnecchi, M. et al. Paracrine action accounts for marked protection of ischemic heart by Aktmodified mesenchymal stem cells. Nat. Med. 11, 367-368 (2005).
91. Roell, W. et al. engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 450, 819-824 (2007).
92. Bu, L. et al. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 460, 113-117 (2009).
93. Webber, M. J. et al. Development of bioactive peptide amphiphiles for therapeutic cell delivery. Acta Biomater. 6, 3-11 (2010).
94. Davis, M. e., Hsieh, P. C., Grodzinsky, A. J. &Lee, R. T. Custom design of the cardiac microenvironment with biomaterials. Circ. Res. 97, 8-15 (2005).
95. Davis, M. e. et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl Acad. Sci. USA 103, 8155-8160 (2006).
96. Yoon, Y. S. et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J. Clin. Invest. 115, 326-338 (2005).
97. Aranguren, X. L. et al. Multipotent adult progenitor cells sustain function of ischemic limbs in mice. J. Clin. Invest. 118, 505-514 (2008).
98. Nygren, J. M. et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat. Med. 10, 494-501 (2004).
99. Dai, W. et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation 112, 214-223 (2005).
100. Wollert, K. C. &Drexler, H. Mesenchymal stem cells for myocardial infarction: promises and pitfalls. Circulation 112, 151-153 (2005).
101. Noiseux, N. et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol. Ther. 14, 840-850 (2006).
102. Field, L. J. Unraveling the mechanistic basis of mesenchymal stem cell activity in the heart. Mol. Ther. 14, 755-756 (2006).
103. Prater, D. N., Case, J., Ingram, D. A. &Yoder, M. C. Working hypothesis to redefine endothelial progenitor cells. Leukemia 21, 1141-1149 (2007).
104. Gnecchi, M., Zhang, Z., Ni, A. &Dzau, v. J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 103, 1204-1219 (2008).
105. Urbich, C. et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell. Cardiol. 39, 733-742 (2005).
106. Korf-Klingebiel, M. et al. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur. Heart J. 29, 2851-2858 (2008).
107. Perez-Ilzarbe, M. et al. Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. Eur. J. Heart Fail. 10, 1065-1072 (2008).
108. Uemura, R., Xu, M., Ahmad, N. &Ashraf, M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ. Res. 98, 1414-1421 (2006).
109. Cho, H. J. et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J. Exp. Med. 204, 3257-3269 (2007).
110. Kamihata, H. et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 104, 1046-1052 (2001).
111. Kawamoto, A. et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 107, 461-468 (2003).
112. Zeng, L. et al. Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation 115, 1866-1875 (2007).
113. erbs, S. et al. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (RePAIR-AMI) trial. Circulation 116, 366-374 (2007).
114. Mirotsou, M. et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc. Natl Acad. Sci. USA 104, 1643-1648 (2007).
115. Burchfield, J. S. et al. Interleukin-10 from transplanted bone marrow mononuclear cells contributes to cardiac protection after myocardial infarction. Circ. Res. 103, 203-211 (2008).
116. Gilchrist, A. et al. Quantitative proteomics analysis of the secretory pathway. Cell 127, 1265-1281 (2006).
117. Bersell, K., Arab, S., Haring, B. &Kühn, B. Neuregulin1/erbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138, 257-270 (2009).
118. Smart, N. et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445, 177-182 (2007).
119. Malik, D. K., Baboota, S., Ahuja, A., Hasan, S. &Ali, J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv. 4, 141-151 (2007).
120. Zhang, G. et al. Controlled release of stromal cell-derived factor-1 alpha in situ increases c-kit+ cell homing to the infarcted heart. Tissue Eng. 13, 2063-2071 (2007).
121. Segers, v. F. et al. Local delivery of proteaseresistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 116, 1683-1692 (2007).
122. Kehat, I. et al. electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat. Biotechnol. 22, 1282-1289 (2004).
123. Ménard, C. et al. Transplantation of cardiaccommitted mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet 366, 1005-1012 (2005).
124. Guan, K. et al. Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 440, 1199-1203 (2006).
125. Conrad, S. et al. Generation of pluripotent stem cells from adult human testis. Nature 456, 344-349 (2008).
126. Brevini, T. A. &Gandolfi, F. Parthenotes as a source of embryonic stem cells. Cell Prolif. 41 (Suppl. 1), 20-30 (2008).
127. Smith, R. R. et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115, 896-908 (2007).
128. Andersen, D. C., Andersen, P., Schneider, M., Jensen, H. B. &Sheikh, S. P. Murine "cardiospheres" are not a source of stem cells with cardiomyogenic potential. Stem Cells 27, 1571-1581 (2009).
129. Wu, S. M., Chien, K. R. &Mummery, C. Origins and fates of cardiovascular progenitor cells. Cell 132, 537-543 (2008).
130. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007).
131. Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920 (2007).
132. Mauritz, C. et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 118, 507-517 (2008).
133. Nelson, T. J. et al. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 120, 408-416 (2009).
134. Carey, B. W. et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc. Natl Acad. Sci. USA 106, 157-162 (2009).
135. Kaji, K. et al. virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458, 771-775 (2009).
136. Huangfu, D. et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat. Biotechnol. 26, 795-797 (2008).
137. Lyssiotis, C. A. et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc. Natl Acad. Sci. USA 106, 8912-8917 (2009).
138. Kolossov, e. et al. engraftment of engineered eS cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J. Exp. Med. 203, 2315-2327 (2006).
139. Kiuru, M., Boyer, J. L., O'Connor, T. P. &Crystal, R. G. Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell 4, 289-300 (2009).
140. Taylor, C. J. et al. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 366, 2019-2025 (2005).
141. Nakajima, F., Tokunaga, K. &Nakatsuji, N. Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells 25, 983-985 (2007).